Pharvaris stock rating reiterated at Buy by H.C. Wainwright

Investing.com - H.C. Wainwright has reiterated its Buy rating and $60.00 price target on Pharvaris B.V. (NASDAQ:PHVS), a $1.7 billion market cap company developing treatments for hereditary angioedema (HAE). The stock currently trades at $23.46, with InvestingPro data showing strong analyst support through multiple upward earnings revisions.

The firm cited strong investor interest following its initiation report, prompting the release of full Q&A discussions with HAE experts and Pharvaris management that detail HAE pathogenesis, treatment paradigms, and the outlook for deucrictibant.

H.C. Wainwright believes Pharvaris is positioned to lead the next phase of HAE treatment with its dual oral formulations that offer injectable-like efficacy, rapid onset, and the convenience of once-daily prevention or single-dose relief.

The company faces several near-term catalysts, including the pivotal Phase 3 RAPIDe-3 on-demand readout expected in 4Q25, Phase 3 CHAPTER-3 prophylaxis data in 2H26, and a potential U.S. new drug application submission for deucrictibant IR in 1H26.

The research note referenced the firm’s October 15 launch report titled "A New CHAPTER in HAE: Dual Formulation Oral Bradykinin Inhibitor to CREAATE Near-Term Value; Initiate Buy and $60 PT."

In other recent news, Pharvaris N.V. announced the pricing of an underwritten public offering expected to raise approximately $175 million in gross proceeds. The offering includes 8.25 million ordinary shares priced at $20.00 per share and pre-funded warrants for 500,000 ordinary shares at $19.99 per warrant. This move is aimed at funding the company’s angioedema programs. Pharvaris also granted underwriters a 30-day option to purchase an additional 1.31 million ordinary shares at the public offering price.

In related developments, BofA Securities upgraded Pharvaris’s stock rating from Underperform to Neutral, citing the company’s strategy to target a broader label for its drug treating bradykinin-mediated angioedema. Meanwhile, Citizens JMP adjusted its price target for Pharvaris to $52.00 from $55.00, maintaining a Market Outperform rating. The firm expressed confidence in Pharvaris management’s execution, noting that Phase 3 data for their on-demand hereditary angioedema treatment is anticipated next quarter. These developments reflect ongoing strategic and financial activities within Pharvaris.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.